Next 10 |
home / stock / iclr / iclr articles
Icon (NASDAQ:ICLR) has outperformed the market over the past 15 years by 6.88% on an annualized basis producing an average annual return of 19.66%....
Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's att...
Icon (NASDAQ:ICLR) has outperformed the market over the past 10 years by 11.78% on an annualized basis producing an average annual return of 22.28%...
Icon (NASDAQ:ICLR) has outperformed the market over the past 20 years by 10.4% on an annualized basis producing an average annual return of 18.29%....
Icon (NASDAQ:ICLR) has outperformed the market over the past 15 years by 8.95% on an annualized basis producing an average annual return of 22.3%. ...
Icon (NASDAQ:ICLR) has outperformed the market over the past 20 years by 11.84% on an annualized basis producing an average annual return of 19.81%...
Icon (NASDAQ:ICLR) has outperformed the market over the past 5 years by 4.31% on an annualized basis producing an average annual return of 17.03%. ...
U.S. stocks were higher, with the Nasdaq Composite gaining more 2% on Thursday. Shares of NICE Ltd. (NASDAQ: NICE) rose sharply during Thursday&rs...
Icon (NASDAQ:ICLR) has outperformed the market over the past 20 years by 11.13% on an annualized basis producing an average annual return of 18.78%...
News, Short Squeeze, Breakout and More Instantly...
ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today announced that Dr. Steve Cutler, CEO of ICON plc, will present at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 1:30pm ET. Any changes to this event and links...
2024-05-31 07:00:07 ET David Windley from Jefferies issued a price target of $390.00 for ICLR on 2024-05-31 05:48:00. The adjusted price target was set to $390.00. At the time of the announcement, ICLR was trading at $322.92. The overall price target consensus is at $265...
Highlights Accelerating mid-term financial outlook supported by positive market environment and strengthened, scaled offering. Continued focus on innovation to drive improved outcomes and efficiency in trial delivery. Updated 2024 financial outlook to incorporate positive impact o...